First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation

ST. LOUIS PARK, Minn., Nov. 09, 2016 (GLOBE NEWSWIRE) —  NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the first use of its DS1000 System in the U.S. as it enrolled the first patient in the RECHORD Trial.

Read more:  First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation